Skip to main content
Top
Published in: Journal of Nephrology 2/2017

01-04-2017 | Original Article

Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature

Authors: Pietro Manuel Ferraro, Gary C. Curhan, Alessandro D’Addessi, Giovanni Gambaro

Published in: Journal of Nephrology | Issue 2/2017

Login to get access

Abstract

Background

Nephrolithiasis is a frequent condition. While it is generally accepted that such condition carries a risk of recurrence over time, the exact risk and its predictors have been rarely quantitated. We aimed to estimate recurrence of kidney stones, overall and in specific subgroups, from randomized controlled trials (RCTs) of calcium stone formers.

Methods

Systematic review of RCTs of adult patients with idiopathic calcium kidney stones. Recurrence rates analyzed in subgroups based on type of intervention and other characteristics, using Poisson regression models.

Results

The analysis included 21 RCTs with 2168 participants over a median follow-up of 3.2 years (range 0.5–9.7). The median recurrence of kidney stones was 15 per 100 person–years (range 0–110). Recurrence was higher in those with two or more previous stone episodes compared to those with a single episode at enrolment (16 vs. 6 per 100 person–years, p < 0.001) and in those untreated or treated with dietary changes compared to those treated with drugs (26 vs. 23 vs. 9 per 100 person–years, p < 0.001). The effect of drugs on recurrence seemed to be beneficial only among those with two or more previous stone episodes.

Conclusions

The overall recurrence rate of stones depends on factors such as previous stone history and type of treatment. Dietary approaches seem to be more effective among single stone formers, whereas drugs seem to be more effective among recurrent stone formers.
Appendix
Available only for authorised users
Literature
2.
go back to reference Fabris A, Lupo A, Fantin F et al (2011) Abnormal arterial stiffness and bone density in calcium renal stone formers. J Am Soc Nephrol JASN 22:388 Fabris A, Lupo A, Fantin F et al (2011) Abnormal arterial stiffness and bone density in calcium renal stone formers. J Am Soc Nephrol JASN 22:388
3.
go back to reference Ferraro PM, Taylor EN, Eisner BH et al (2013) History of kidney stones and the risk of coronary heart disease. JAMA J Am Med Assoc 310(4):408–415CrossRef Ferraro PM, Taylor EN, Eisner BH et al (2013) History of kidney stones and the risk of coronary heart disease. JAMA J Am Med Assoc 310(4):408–415CrossRef
4.
go back to reference Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848–857CrossRefPubMed Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848–857CrossRefPubMed
5.
6.
go back to reference Borghi L, Schianchi T, Meschi T et al (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346(2):77–84CrossRefPubMed Borghi L, Schianchi T, Meschi T et al (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346(2):77–84CrossRefPubMed
7.
go back to reference Schissel BL, Johnson BK (2011) Renal stones: evolving epidemiology and management. Pediatr Emerg Care 27(7):676–681CrossRefPubMed Schissel BL, Johnson BK (2011) Renal stones: evolving epidemiology and management. Pediatr Emerg Care 27(7):676–681CrossRefPubMed
8.
go back to reference Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation, 1st edn. OUP, Oxford Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation, 1st edn. OUP, Oxford
9.
go back to reference Fink HA, Wilt TJ, Eidman KE et al (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158(7):535–543CrossRefPubMed Fink HA, Wilt TJ, Eidman KE et al (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158(7):535–543CrossRefPubMed
11.
go back to reference Gambaro G, Reis-Santos JM, Rao N (2004) Nephrolithiasis: why doesn’t our “learning” progress? Eur Urol 45(5):547–556 (discussion 556) CrossRefPubMed Gambaro G, Reis-Santos JM, Rao N (2004) Nephrolithiasis: why doesn’t our “learning” progress? Eur Urol 45(5):547–556 (discussion 556) CrossRefPubMed
12.
go back to reference Gambaro G, Valente ML, Zanetti E et al (2006) Mild tubular damage induces calcium oxalate crystalluria in a model of subtle hyperoxaluria: evidence that a second hit is necessary for renal lithogenesis. J Am Soc Nephrol JASN 17(8):2213–2219CrossRefPubMed Gambaro G, Valente ML, Zanetti E et al (2006) Mild tubular damage induces calcium oxalate crystalluria in a model of subtle hyperoxaluria: evidence that a second hit is necessary for renal lithogenesis. J Am Soc Nephrol JASN 17(8):2213–2219CrossRefPubMed
13.
go back to reference Ettinger B (1976) Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Am J Med 61(2):200–206CrossRefPubMed Ettinger B (1976) Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Am J Med 61(2):200–206CrossRefPubMed
14.
go back to reference Smith MJ (1977) Placebo versus allopurinol for renal calculi. J Urol 117(6):690–692PubMed Smith MJ (1977) Placebo versus allopurinol for renal calculi. J Urol 117(6):690–692PubMed
15.
go back to reference Johansson G, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B (1982) Effects of magnesium hydroxide in renal stone disease. J Am Coll Nutr 1(2):179–185CrossRefPubMed Johansson G, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B (1982) Effects of magnesium hydroxide in renal stone disease. J Am Coll Nutr 1(2):179–185CrossRefPubMed
16.
go back to reference Scholz D, Schwille PO, Sigel A (1982) Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 128(5):903–907PubMed Scholz D, Schwille PO, Sigel A (1982) Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 128(5):903–907PubMed
17.
go back to reference Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215(4):383–389CrossRefPubMed Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215(4):383–389CrossRefPubMed
18.
go back to reference Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315(22):1386–1389CrossRefPubMed Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315(22):1386–1389CrossRefPubMed
19.
go back to reference Mortensen JT, Schultz A, Ostergaard AH (1986) Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol 18(3):265–269CrossRefPubMed Mortensen JT, Schultz A, Ostergaard AH (1986) Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol 18(3):265–269CrossRefPubMed
20.
go back to reference Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22(Suppl 6):S78–S86CrossRefPubMed Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22(Suppl 6):S78–S86CrossRefPubMed
21.
go back to reference Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150(6):1761–1764PubMed Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150(6):1761–1764PubMed
22.
go back to reference Hofbauer J, Höbarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 73(4):362–365CrossRefPubMed Hofbauer J, Höbarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 73(4):362–365CrossRefPubMed
23.
go back to reference Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155:839–843CrossRefPubMed Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155:839–843CrossRefPubMed
24.
go back to reference Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT (1996) Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 144(1):25–33CrossRefPubMed Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT (1996) Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 144(1):25–33CrossRefPubMed
25.
go back to reference Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069–2073CrossRefPubMed Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069–2073CrossRefPubMed
26.
go back to reference Kocvara R, Plasgura P, Petrík A, Louzenský G, Bartonícková K, Dvorácek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84(4):393–398CrossRefPubMed Kocvara R, Plasgura P, Petrík A, Louzenský G, Bartonícková K, Dvorácek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84(4):393–398CrossRefPubMed
27.
go back to reference Di Silverio F, Ricciuti GP, D’Angelo AR, Fraioli A, Simeoni G (2000) Stone recurrence after lithotripsy in patients with recurrent idiopathic calcium urolithiasis: efficacy of treatment with fiuggi water. Eur Urol 37(2):145–148CrossRefPubMed Di Silverio F, Ricciuti GP, D’Angelo AR, Fraioli A, Simeoni G (2000) Stone recurrence after lithotripsy in patients with recurrent idiopathic calcium urolithiasis: efficacy of treatment with fiuggi water. Eur Urol 37(2):145–148CrossRefPubMed
28.
go back to reference Soygür T, Akbay A, Küpeli S (2002) Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol 16(3):149–152CrossRefPubMed Soygür T, Akbay A, Küpeli S (2002) Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol 16(3):149–152CrossRefPubMed
29.
go back to reference Micali S, Sighinolfi MC, Celia A et al (2006) Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 176(3):1020–1022CrossRefPubMed Micali S, Sighinolfi MC, Celia A et al (2006) Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 176(3):1020–1022CrossRefPubMed
30.
go back to reference Sarica K, Inal Y, Erturhan S, Yağci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34(3):184–189CrossRefPubMed Sarica K, Inal Y, Erturhan S, Yağci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34(3):184–189CrossRefPubMed
31.
go back to reference Dussol B, Iovanna C, Rotily M et al (2008) A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. Nephron Clin Pract 110(3):c185–c194CrossRefPubMed Dussol B, Iovanna C, Rotily M et al (2008) A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. Nephron Clin Pract 110(3):c185–c194CrossRefPubMed
32.
go back to reference Lojanapiwat B, Tanthanuch M, Pripathanont C et al (2011) Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. Int Braz J Urol 37(5):611–616CrossRefPubMed Lojanapiwat B, Tanthanuch M, Pripathanont C et al (2011) Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. Int Braz J Urol 37(5):611–616CrossRefPubMed
Metadata
Title
Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature
Authors
Pietro Manuel Ferraro
Gary C. Curhan
Alessandro D’Addessi
Giovanni Gambaro
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 2/2017
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-016-0283-8

Other articles of this Issue 2/2017

Journal of Nephrology 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine